Corvilain J, Manderlier T, Struyven J, Fuss M, Bergans A, Nijs N, Brauman H
Horm Metab Res. 1977 May;9(3):239-42. doi: 10.1055/s-0028-1093545.
Immunoreactive PTH was measured by amino terminal and carboxyl terminal specific assays in the femoral artery, the right renal vein and the suprahepatic vein of ten hyperparathyroid patients. A marked arterio venous difference for amino terminal immunoreactivity was observed in the kidney and the liver. In contrast, the arterio venous difference for carboxyl terminal immunoreactivity was small in the kidney and not significantly in the liver. It is concluded that intact PTH and possibly amino terminal fragments of the hormone are metabolized by the kidney and the liver. Considering the fact that a carboxyl terminal specific antiserum is also capable of recognizing intact hormone, the finding of a small positive arterio venous difference for carboxyl terminal immunoreactivity does not permit us to exclude the possibility that the kidney and/or the liver are capable of generating carboxyl terminal fragments.
采用氨基末端和羧基末端特异性检测方法，对10例甲状旁腺功能亢进患者的股动脉、右肾静脉和肝上静脉中的免疫反应性甲状旁腺激素（PTH）进行了测定。在肾脏和肝脏中观察到氨基末端免疫反应性存在明显的动静脉差异。相比之下，羧基末端免疫反应性的动静脉差异在肾脏中较小，在肝脏中则不显著。结论是完整的PTH以及可能的该激素氨基末端片段在肾脏和肝脏中被代谢。鉴于羧基末端特异性抗血清也能够识别完整激素这一事实，羧基末端免疫反应性存在较小的正向动静脉差异这一发现，并不能使我们排除肾脏和/或肝脏能够产生羧基末端片段的可能性。
